Dr Michelle Bradney is the Chief Executive Officer of Cerulea Clinical Trials, bringing more than 20 years of leadership experience across pharmaceutical and biotechnology sectors.

She has deep expertise in the execution of high stakes and complex regulatory, clinical development and operational delivery across Europe, the USA, Australia and Asia.

Throughout her career, Michelle has played pivotal roles in establishing and building clinical research departments, and overseeing Phase I–IV, investigator-initiated (IIT) and real-world evidence (RWE) trials.

Before joining Cerulea, Michelle served as Chief Operating Officer at OccuRx and held senior positions at Allergan, where she led ophthalmic clinical monitoring operations.

Michelle holds a PhD from the University of Melbourne and is a graduate of the Australian Institute of Company Directors (GAICD). She contributes to governance in the life sciences sector as a board observer with Medicines Australia and as a member of the Women on Boards Naomi Simson Syndicate.

Passionate about accelerating access to innovative medicines, Michelle is committed to improving outcomes for people living with eye disease by bringing cutting-edge treatments to patients today.

Professor Lyndell Lim is a uveitis and medical retina subspecialist and leads CERA’s Uvietis and Vascular Retinal Disease Research.

After completing her ophthalmology training in Melbourne, Professor Lim then completed two Fellowships – one in medical retina at the Royal Victorian Eye and Ear Hospital, and one in uveitis/ocular inflammatory disease at the Casey Eye Institute, Portland, Oregon, USA.

Prof Lim’s main research interests are clinical studies in the field of uveitis and ocular immunology, and diabetic retinopathy. Her team runs both investigator-initiated and sponsored clinical trials that aim to investigate new treatments in a variety of ophthalmic diseases.

Marios Constantinou is the Chief Clinical Operations Officer at Cerulea.

He is an allied health clinician (Orthoptist) with over 20 years’ experience in clinical trials (Pharmaceutical and Investigator Initiated).

His extensive years of experience has afforded him of the opportunity to work with many leading Centre for Eye Research Australia (CERA) investigators and study teams, and sponsor companies. Over the last 10 years, he has been responsible for managing CERAs Clinical Trials Centre Operations, leading a high-calibre clinical trial team across all ophthalmic indications and trial phases. He has proven capabilities in clinical operations, quality assurance, clinical trial coordination and financial management.

Thuy Chau is a Senior Clinical Research and Start Up Manager at Cerulea Clinical Trials.

After graduating from La Trobe University in 2011 as an Orthoptist, he started his career as an orthoptic clinical/research study coordinator at Vision Eye Institute. He joined the Centre for Eye Research Australia in 2015 as a study coordinator, and has since been part of both sponsored and investigator-initiated trials for a wide range of eye conditions.

In 2024 he joined Cerulea’s inaugural team as a senior manager.

Angelica De Guzman is a clinical Research Manager at Cerulea Clinical Trials.

She started her career as an ophthalmic technician and clinical trials research assistant in Aukland, New Zealand. She joined the Centre for Eye Research Australia in 2020 and has coordinated a broad range of trials for conditions including diabetic macular edema, age-related macular degeneration and ocular discomfort.

In addition to coordinating local trials at Cerulea, she oversees multi-site studies at ophthalmology clinics across the state.

Lisa Lombardi is an Optometrist, Clinical Research Manager at Cerulea Clinical Trials and Honorary Researcher at the Royal Victorian Eye and Ear Hospital.  She completed her Bachelor of Optometry degree in 2007, from the University of Melbourne, graduating with therapeutic endorsement and Post Graduate Diploma in Advanced Clinical Optometry in 2009.  Lisa is also a committee member of the Vision2020 Prevention and Early Intervention committee. She is currently managing the conduct of clinical trials involving gene therapies and photoswitch technology for inherited retinal diseases.  She also works with the Bionic Eye Unit at CERA exploring vision processing methods in patients with end-stage retinitis pigmentosa implanted with a suprachoroidal retinal prosthesis and developing a new functional assessment tool which captures multisensory performance in the real-world environment.

Jacqui Henwood is an optometrist and clinical research manager with a strong background in both clinical practice and ophthalmic research. She completed her Doctor of Optometry at the University of Melbourne in 2017 and has since worked across a variety of clinical settings, including hospital, corporate, independent, and domiciliary optometry.

In 2021, Jacqui joined the ophthalmic epidemiology team at the Centre for Eye Research Australia (CERA) as Research Project Manager, where she led a multi-site MRFF artificial intelligence (AI) grant. This project explored the integration of AI with retinal imaging to enhance diagnosis, improve referral pathways, and support standardised care in the detection of common eye conditions and cardiovascular risk.

In 2024, Jacqui joined Cerulea to coordinate inherited retinal disease (IRD) clinical trials with adults and adolescents. She stepped into the role of Clinical Research Manager in 2025, where she manages clinical trials from initiation to completion and supports the delivery of innovative research.

Her professional interests include ocular pathology, inherited retinal disease, myopia control, and emerging technologies in eye care. Jacqui is particularly passionate about advancing research that improves patient outcomes and bridges the gap between research and real-world clinical application.

Our Board Directors provide strategic oversight and guidance, contributing extensive expertise and knowledge of clinical trials, medical research and  biopharmaceutical and device development.

Cerulea Clinical Trials’ state-of-the-art facilities and experienced team deliver innovation and excellence in ophthalmic clinical trials.